Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22033516 | 0.76 | MAPT (0.59) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL3761879 | 0.75 | MAPT (0.46) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL2299306 | 0.72 | KDM4E (0.37) | MAPTSMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12232008 | 0.70 | MAPT (0.52) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL30019714 | 0.69 | MAPT (0.76) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL11987005 | 0.69 | MAPT (0.76) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL197523 | 0.69 | MAPT (1.00) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL19687289 | 0.68 | MAPT (0.53) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL19686873 | 0.68 | MAPT (0.53) | RAB9AMAPTSMN1; SMN2NPC1ATM | |
| SCHEMBL12532375 | 0.67 | RAB9A (0.68) | RAB9AMAPTSMN1; SMN2NPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1942890-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | RAB9A 2043/4885MAPT 3843/4885SMN1; SMN2 4838/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | RAB9A 2043/4885MAPT 3843/4885SMN1; SMN2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.